CVTX - CV Therapeutics, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (356)	11/13/2008 10:05:39 AM
From: scaram(o)uche	of 411

>> Well it's still not first line << Sorry.... been very busy. Peter.... I read the new label again, and believe that it is first line. First line with some very nice commentary to boot. IMO, this all evolves from Lange's battle to demo that BENEFICIAL elevations of QTc interval can exist. from the press release..... According to the revised labeling, Ranexa is indicated for the treatment of chronic angina and may be used alone or in combination with traditional therapies for chronic angina, such as beta blockers, calcium channel blockers and nitrates, and common cardio-protective treatments for cardiovascular disease such as anti-platelet therapy, lipid-lowering therapy, ACE inhibitors and angiotensin receptor blockers. from the label...... Ranexa is indicated for the treatment of chronic angina. ranexa.com I'm not saying that you're wrong about which drugs will be selected first by physicians. But from everything that I've seen? I'd request Ranexa, if I were a new onset patient.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next